Explore a diverse range of topics and expertise through our seminar series at the Blumberg Institute. Our Industry Speakers series offers valuable industry insights, while the Young Investigator Seminars showcase cutting-edge research. Our Invited Seminars feature esteemed guests. Join us in cultivating collaboration, fostering innovation, and promoting academic excellence.
All seminars, unless noted, take place at our headquarters at the Pennsylvania Biotechnology Center at 3805 Old Easton Road, Doylestown, PA 18902, in Room 3100.
No registration required.
May 1, 2025, 10 a.m.
Felicia Goodrum, PhD, Associate Dept. Head and Professor, Department of Immunobiology, University of Arizona
Virus-Host interactions regulating human Cytomegalovirus Latency and Reactivation
May 1, 2025, 11:15 a.m.
Tanner Grudda, BS, PhD Candidate, Johns Hopkins Bloomberg School of Public Health
HBV splice variants are more pronounced and stable in people with HIV/HBV co-infection compared to HBV mono-infection
May 6, 2025, 11 a.m.
Susan R. Weiss, PhD, Professor and Vice Chair Department of Microbiology, Perleman School of Medicine, University of Pennsylvania
Coronavirus activation and antagonism of interferon signaling pathways
May 15, 2025, 11 a.m.
Eda Canales, PhD, Director, Medicinal Chemistry, Gilead Sciences
Lenacapavir, a First-in-class Long-Acting HIV Capsid Inhibitor
July 3, 2025, 11 a.m.
Alison Axtman, PhD, Assistant Professor, Division of Chemical Biology and Medicinal Chemistry, Principal Investigator of Medicinal Chemistry in SGC-UNCD
TBD
(If Available)
April 24, 2025
Zhengyin Yan, PhD, Distinguished Scientist, Genentech
Dynamic free drug fraction: concept, methodolgy and impact on DMPK
March 20, 2025
Joseph Che-Yen Wang, PhD
A Structural Journey: Unraveling Hepatitis B Virus Molecular Architecture with Cryo-EM
Feb. 13, 2025
Emma Parmee, DPhil
New Directions in Drug Discovery: Expanding Exploration of Chemical Space
December 12, 2024
Harry Janssen, MD, PhD
Chair Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands
Hepatitis B: How to transfer a suppressive into a curative treatment?
Nov. 26 2024
Austin Argentieri, PhD
Research Fellow in Analytic and Translational Genetics Unit at Massachusetts General Hospital
Leveraging large-scale population biobank data to study aging and chronic age-related diseases
Nov. 7, 2024
Peter Tompa, PhD, Professor emeritus/VIB-VUB Center for Structural Biology, Brussels
Targeting biomolecular condensation: a new modality in drug development
September 26, 2024
Yingpu Yu, PhD
Research Associate, laboratory of Virology and Infectious disease, The Rockefeller University
An RNA-based system to study hepatitis B virus replication and evaluate antivirals
September 19, 2024
Mark Yorek, PhD
Professor of Medicine, University of Iowa & Associate Chief of Staff Iowa City VA Health Care System
From Bench to Bedside: Omega-3 Polyunsaturated Fatty Acids as a Potential Treatment for Diabetic Peripheral Neuropathy
September 18, 2024
Rui Liu, PhD
Research Assistant Professor, University of Notre Dame
Short Stories in the Medicinal Chemistry
August 15, 2024
Dr. Albert Jeltsch, PhD
Prof. of Biochemistry, University of Stuttgart, German
Analysis of the specificities of DNA and protein methyltransferases leading to novel insights into epigenetic processes
August 7, 2024
Dr. Llorente Bonoga, PhD
Senior Director, GRACS CMC
Enabling First in Human Studies: Regulatory Requirements, Regulatory Documentation and CMC Risks and Mitigations Part 2:
“Regulatory CMC Considerations for Clinical Studies”
July 15, 2024
Dr. Brett Tounge, PhD
Co-Founder and Managing Partner, Chairman at Mebias Discovery
The discovery and development of non-addictive analgesics utilizing Mebias’ novel drug discovery platform
June 13, 2024
Maarouf Hoteit, MD, AGAF
Associate Professor of Clinical Medicine, University of Pennsylvania
May 30, 2024
Dr, Manisha Srivastava, PhD
Associate Director, GRACS CMC
Enabling First in Human Studies: Regulatory Requirements, Regulatory Documentation and CMC Risks and Mitigations, Part 1: “Global CMC Documentation and CMC Strategies Enabling Global Phase 1 Studies”
May 16, 2024
Heather Finlay, PhD
VP Medicinal Chemistry, Exelixis
April 25, 2024
Shihyun You, PhD
Professor of Biochemistry, University of Stuttgart, German
April 11, 2024
Targeted Protein Degradation for Antiviral Drug Discovery
March 28, 2024
Pekka Katajisto, PhD
Professor, University of Helsinki and Karolinska Institute
Distinguished Speaker Series
March 14, 2024
George Yeoh, BSc (Hons), PhD
Laboratory Head, Perkins Institute of Medical Research
February 22, 2024
Dr. Theo Heller, MD
Senior Investigator NIH, Bethesda, MD
HDV: D is for Diabolical, or “Are we Winning Yet?”
January 11, 2024
Yongzhen Liu, PhD
Postdoctoral Research Fellow in the Department of Molecular Biology at Princeton University
Outstanding Young Scientist Series